Introduction
============

Insulin resistance (IR) is a reduction in reaction or sensitivity to insulin and was first presented by Reaven in 1988 ([@b1-etm-06-05-1237]). IR is considered to be the common cause of impaired glucose tolerance, diabetes, obesity, dyslipidemia and hypertensive diseases. IR syndrome is associated with multiple metabolic disorders and was renamed metabolic syndrome (MS) by Zimmet *et al* in 1997 ([@b2-etm-06-05-1237]). A previous study ([@b3-etm-06-05-1237]) identified that MS is closely associated with atherosclerosis (AS) and numerous factors, including cytokines, are involved in AS formation. Cathepsin S (CatS) is a cysteine protease, an important lysosomal protease and the predominant cathepsin. CatS is released from primary cultured microglia and regulated by the P2X7 receptor ([@b4-etm-06-05-1237]), which is associated with matrix metalloproteinases and serine protease, and involved in extracellular proteolytic degradation. In addition, CatS has important physiological functions in the extracellular environment, including degradation of the extracellular matrix (ECM), regulation of growth factors, vascular proliferation of various cytokines, and cell migration, proliferation and apoptosis. Sukhova *et al* ([@b5-etm-06-05-1237]) demonstrated that CatS expression is increased in atherosclerotic sites. Furthermore, studies have shown that CatS is important for the formation and development of AS ([@b6-etm-06-05-1237]--[@b9-etm-06-05-1237]). Type 2 diabetes is a polygenic, hereditary, metabolic disease and the main pathophysiological mechanisms are IR and insufficient insulin secretion.

Since CatS, MS and AS are closely associated with each other, IR is one of the most important pathophysiological mechanisms of type 2 diabetes and AS is one of the pathological features of diabetic vascular complications. However, whether CatS is involved in the pathophysiological mechanisms of type 2 diabetes is yet to be elucidated. A previous study demonstrated that the increased expression of CatS was in parallel with an increase in proinflammatory cytokine levels during the development of autoimmune inflammatory diseases in the non-obese diabetic (NOD) mouse disease model ([@b10-etm-06-05-1237]). The present study aimed to compare the levels of CatS between patients with type 2 diabetes and healthy individuals, in order to investigate the changes in CatS expression and the possible correlation between CatS and IR.

Patients and methods
====================

Patients
--------

A total of 51 patients with type 2 diabetes (Group DM) were recruited from the Department of Endocrinology, Anhui Provincial Hospital Affiliated to Anhui Medical University (Hefei, China). All patients (age range, 38--80 years) coincided with the 1999 World Health Organization standards for diabetes diagnosis and classification ([@b11-etm-06-05-1237]). Exclusion criteria comprised patients who had heart, liver or pancreatic diseases; primary or secondary renal diseases (with the exception of diabetic nephropathy); inflammatory tumor or immunity diseases; impaired glucose tolerance induced by glucocorticoid and steroidal agents; and acute complications or serious chronic complications of diabetes mellitus, including ketoacidosis, hyperosmolar coma and lactic acidosis. Forty-nine healthy individuals without diabetes, infection, tumors and autoimmune diseases were chosen as the normal controls (Group NC; 25 males and 24 females). A total of 51 diabetic patients in DM group included 26 males and 25 females. The study was approved by the local research ethics committee (Anhui Provincial Hospital, Anhui, China) and written informed consent was obtained from all patients before the study commenced.

Methods
-------

The gender, age, height, body weight, systolic pressure and diastolic pressure of the patients were recorded, and the body mass index (BMI) and the homeostatic model assessment index of IR (HOMA-IR) were calculated in all participants. Venous blood samples were collected to measure serum creatinine, cholesterol (TCH), triglyceride (TG), very low density lipoprotein (VLDL), fasting plasma glucose (FPG), insulin and glycosylated hemoglobin A1c (HbA1c) levels following \>8 h of overnight fasting. Simultaneously, a serum sample was collected and preserved at −80°C to test for the expression of CatS.

Serum CatS levels were determined using a sandwich enzyme immunoassay (ELISA; Krka, d.d., Novo mesto, Riga, Slovenia; Riga, Slovenia; Human Cathepsin S) according to the manufacturer's instructions. Serum samples were diluted 1:1 with 0.9% physiological saline, and then added to the pre-coated ELISA plate (100 *μ*l per well). Plates were incubated overnight at 4°C, washed and incubated with conjugated solution for 2 h at 37°C. Plates were then developed by treatment with 3,3′,5,5′-tetramethylbenzidine (TMB) and H~2~SO~4~ solution according to the manufacturer's instructions of the ELISA kit. The serum concentrations of CatS were determined from standard curves derived from the provided calibrators, and ranged from 0.1 to 4.4 nmol/l. The serum biochemical indices were measured using an automatic biochemical analyzer (Hitachi no. 7600-020; Hitachi High-Technologies Corporation, Tokyo, Japan).

Statistical analysis
--------------------

Clinical data and serum Cat S levels were analyzed using the nonparametric Wilcoxon test, linear and multiple linear regression. The HOMA-IR was converted into logarithms to achieve approximate normality. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Comparison of the clinical data between Group NC and Group DM
-------------------------------------------------------------

As shown in [Table I](#t1-etm-06-05-1237){ref-type="table"}, a comparison of the clinical data between Group NC and Group DM indicated no significant differences in age, and serum creatinine and TCH levels. However, the CatS, FPG, VLDL and TG levels in Group DM were significantly higher than those in Group NC (P=0.000, 0.000, 0.014 and 0.020, respectively).

Correlation between serum CatS levels and various clinical indices
------------------------------------------------------------------

Changes in the serum levels of CatS were significantly associated with TG and VLDL levels (P\<0.05 for both); however, no significant correlations were identified between serum CatS levels and age, disease course, blood pressure, TCH, BMI, FPG, Cr, HbAc1 and HOMA-IR ([Table II](#t2-etm-06-05-1237){ref-type="table"}).

Correlation between serum CatS levels and clinical data in Group DM at different HOMA-IR levels
-----------------------------------------------------------------------------------------------

The third quartile is 2.095. Regardless of whether the HOMA-IR level was low (\<2.095) or high (≥2.095), there no significant correlations were identified between the serum levels of CatS and age, disease course, blood pressure, TCH, BMI, FPG, Cr, TG, VLDL, HbAc1 and HOMA-IR ([Tables III](#t3-etm-06-05-1237){ref-type="table"} and [IV](#t4-etm-06-05-1237){ref-type="table"}, respectively).

Correlation between serum CatS level and clinical data in Group DM at different HbA1c levels
--------------------------------------------------------------------------------------------

When the HbA1c level was \<9% ([Table V](#t5-etm-06-05-1237){ref-type="table"}), there were no significant correlations between serum CatS and age, disease course, blood pressure, TCH, BMI, FPG, Cr, TG, VLDL, HbAc1 and HOMA-IR. However, when the HbA1c levels were ≥9%, significant correlations were identified between serum CatS levels and disease course, TG and VLDL levels (P=0.025, 0.021 and 0.022, respectively; [Table VI](#t6-etm-06-05-1237){ref-type="table"}).

Correlation between serum CatS levels and clinical data in Group DM at different BMI levels
-------------------------------------------------------------------------------------------

At a BMI of \<25 kg/m^2^, the serum CatS level was significantly associated with disease course, and TG and VLDL levels (P=0.033, 0.027 and 0.023, respectively; [Table VII](#t7-etm-06-05-1237){ref-type="table"}). However, no significant correlations were determined between those factors when the BMI was ≥25 kg/m^2^ ([Table VII](#t7-etm-06-05-1237){ref-type="table"}). In addition, there were no significant correlations between serum CatS and age, blood pressure, TCH, BMI, FPG, Cr, HbAc1 and HOMA-IR regardless of whether the BMI was \<25 or ≥25 kg/m^2^.

Discussion
==========

CatS was first identified in hematopoietic cell endosomes, which belong to the non-glycosylated papain-like single-chain protease family, and demonstrates proteolytic and endopeptidase effects. Numerous studies have shown that CatS is associated with AS, coronary heart disease and cancer. However, few studies have identified a correlation between CatS and diabetes. In animal models, deletion of the CatS gene resulted in immunity to type 1 diabetes mellitus in certain NOD mice ([@b12-etm-06-05-1237]). The present study indicated that CatS levels were significantly higher in patients with type 2 diabetes than those in the normal controls, and this is consistent with the findings of Liu *et al* ([@b13-etm-06-05-1237]). The current study suggests that CatS may be involved in the occurrence and development of diabetes.

IR is a one of the key pathophysiological mechanisms of type 2 diabetes and serum CatS levels are elevated in patients with type 2 diabetes. Therefore, it is necessary to investigate the association between serum CatS concentration and IR in patients with type 2 diabetes. The hyperinsulinemic-euglycemic clamp test is the gold standard for evaluating IR. In addition, BMI, waist circumference, waist to hip ratio, fasting insulin, fasting blood glucose, Shima Soku used the insulin action index (IAI) and HOMA-IR, may also be used as auxiliary indices for evaluating IR. The present study selected BMI and HOMA-IR as the indices of IR. Through hierarchical analysis, no significant correlations between serum CatS and BMI and HOMA-IR were detected. This suggests that HOMAIR, serum CatS and IR are independent of each other, and that CatS may be involved in the occurrence and development of diabetes as an independent factor.

Due to reductions in lipoprotein lipase activity, the TG levels readily increase and VLDL clearance decreases after eating in patients with diabetes, and the accumulation of VLDL increases. Increases in TG levels in the skeletal muscle are also considered to be one of the causes of IR ([@b14-etm-06-05-1237]). The present study identified that serum CatS levels were significantly associated with TG and VLDL levels when the HbA1c level was \>9% or the BMI was \<25 kg/m^2^, respectively. The exact mechanisms responsible for this remain unclear, but may be related to postprandial glucose. In addition, it has been indicated that CatS promotes fat formation, particularly in the early stages of adipocyte differentiation, which suggests that CatS may be involved in the pathophysiological mechanisms of lipid metabolism.

The duration of diabetes (disease course) is correlated with decreased B cell function. The present study demonstrates a significant correlation between serum CatS and diabetes course when the HbA1c level is \>9% or the BMI is \<25 kg/m^2^. However, the precise mechanisms require further investigation.

It has been demonstrated that patients with type 2 diabetes have a low-grade inflammatory state *in vivo* ([@b15-etm-06-05-1237]). Inflammation may cause IR and is involved in associated diseases, including diabetes, metabolic syndrome and AS. Jobs *et al* ([@b16-etm-06-05-1237]) identified that serum CatS levels were associated with C-reactive protein, which is an important indicator of inflammation. In addition, Naour *et al* ([@b17-etm-06-05-1237]) indicated that CatS may also be involved in the energy balance in adipose tissue and circulation. These studies suggest that serum CatS may be independent of IR, and involved in the occurrence and development of diabetes through certain pathways, including the inflammatory response.

A limitation of the present study is that the sample size was relatively low, which may have affected the HOMA-IR results. In addition, more precise methods for the assessment of IR, including glucose clamp experiments, could have been used. In addition, the related inflammatory indices and postprandial blood glucose levels require analysis

In conclusion, the present study demonstrates that serum CatS levels are significantly increased in patients with type 2 diabetes, which reflects their inflammatory state and shows no significant correlation with IR. The precise mechanisms responsible for this require further investigation.

###### 

Comparison of the clinical data between Group NC and Group DM.

  Clinical index        Group DM      Group NC      P-value
  --------------------- ------------- ------------- ---------
  Age (year)            55.84±10.91   60.43±1.87    0.065
  Serum Cr (*μ*mol/l)   79.76±43.35   79.85±14.51   0.045
  TCH (mmol/l)          4.96±1.24     4.54±0.91     0.109
  VLDL (mmol/l)         0.98±0.63     0.78±0.74     0.014
  TG (mmol/l)           2.18±1.43     1.72±1.66     0.020
  FPG (mmol/l)          11.53±3.88    5.19±0.74     0.000
  CatS (nmol/l)         0.46±0.01     0.39±0.01     0.000

Group NC, normal control; Group DM, patients with type 2 diabetes; Cr, creatinine; TCH, cholesterol; VLDL, very low density lipoprotein; TG, triglyceride; FPG, fasting plasma glucose; CatS, cathepsin S.

###### 

Correlation between serum CatS and other clinical indices in Group DM.

  Clinical index        Mean ± sd     CatS             
  --------------------- ------------- ------- -------- -------
  Age (year)            55.84±10.91   0.024   0.001    0.274
  Course (year)         5.59±0.74     0.074   −0.005   0.054
  SBP (mmHg)            134.76±3.21   0.008   0.000    0.524
  DBP (mmHg)            77.72±1.16    0.005   −0.001   0.623
  BMI (kg/m^2^)         23.28±0.44    0.033   0.005    0.201
  FPG (mmol/l)          11.53±3.88    0.018   −0.003   0.348
  Serum Cr (*μ*mol/l)   79.76±43.35   0.036   0.000    0.180
  TCH (mmol/l)          4.96±1.24     0.015   0.009    0.398
  TG (mmol/l)           2.18±1.43     0.108   0.021    0.019
  VLDL (mmol/l)         0.98±0.63     0.113   0.048    0.016
  HbA1c (%)             12.59±0.67    0.000   0.000    0.895
  HOMA-IR               1.62±0.11     0.002   −0.006   0.732

CatS, cathepsin S; Group DM, patients with type 2 diabetes; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; FPG, fasting plasma glucose; Cr, creatinine; TCH, cholesterol; TG, triglyceride; VLDL, very low density lipoprotein; HbAlc, glycosylated hemoglobin; HOMA-IR, homeostatic model assesment index of insulin resistance.

###### 

Correlation between serum CatS levels and clinical data in Group DM at a HOMA-IR level \<2.095.

  Clinical index        Mean ± SD      CatS             
  --------------------- -------------- ------- -------- -------
  Age (year)            55.03±10.29    0.009   0.001    0.577
  Course (year)         5.95±5.42      0.070   −0.005   0.110
  SBP (mmHg)            135.74±24.42   0.004   0.000    0.724
  DBP (mmHg)            76.63±8.52     0.009   −0.001   0.577
  BMI (kg/m^2^)         22.67±2.93     0.037   0.006    0.249
  FPG (mmol/l)          10.95±3.79     0.016   −0.003   0.443
  Serum Cr (*μ*mol/l)   78.33±45.38    0.018   0.000    0.423
  TCH (mmol/l)          4.86±1.27      0.016   0.009    0.444
  TG (mmol/l)           2.04±1.38      0.098   0.021    0.055
  VLDL (mmol/l)         0.93±0.62      0.094   0.047    0.061
  HbA1c (%)             11.55±3.24     0.037   −0.006   0.245
  HOMA-IR               1.28±0.49      0.015   0.023    0.470

CatS, cathepsin S; Group DM, patients with type 2 diabetes; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; FPG, fasting plasma glucose; Cr, creatinine; TCH, cholesterol; TG, triglyceride; VLDL, very low density lipoprotein; HbAlc, glycosylated hemoglobin; HOMA-IR, homeostatic model assesment index of insulin resistance.

###### 

Correlation between serum CatS levels and clinical data in Group DM at a HOMA-IR level ≥2.095.

  Clinical index        Mean ± SD      CatS             
  --------------------- -------------- ------- -------- -------
  Age (year)            58.23±12.68    0.132   0.002    0.223
  Course (year)         4.54±4.94      0.101   −0.006   0.290
  SBP (mmHg)            131.92±18.43   0.053   0.001    0.432
  DBP (mmHg)            80.92±6.77     0.003   0.001    0.857
  BMI (kg/m^2^)         25.08±3.07     0.072   0.008    0.375
  FPG (mmol/l)          13.20±3.76     0.023   −0.003   0.622
  Serum Cr (*μ*mol/l)   83.95±38.15    0.241   0.001    0.089
  TCH (mmol/l)          5.26±1.15      0.018   0.010    0.664
  TG (mmol/l)           2.59±1.58      0.191   0.024    0.135
  VLDL (mmol/l)         1.15±0.67      0.231   0.061    0.097
  HbA1c (%)             15.65±7.02     0.165   0.005    0.169
  HOMA-IR               2.63±0.58      0.182   −0.063   0.146

CatS, cathepsin S; Group DM, patients with type 2 diabetes; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; FPG, fasting plasma glucose; Cr, creatinine; TCH, cholesterol; TG, triglyceride; VLDL, very low density lipoprotein; HbAlc, glycosylated hemoglobin; HOMA-IR, homeostatic model assesment index of insulin resistance.

###### 

Correlation between serum CatS levels and clinical data in Group DM with a HbA1c level \<9%.

  Clinical index        Mean ± SD      CatS                
  --------------------- -------------- ------- ----------- -------
  Age (year)            58.60±12.73    0.019   0.001       0.627
  Course (year)         6.40±5.15      0.008   −0.002      0.753
  SBP (mmHg)            136.47±23.83   0.207   0.002       0.088
  DBP (mmHg)            79.40±8.75     0.008   0.001       0.745
  BMI (kg/m^2^)         23.24±2.54     0.032   0.007       0.523
  FPG (mmol/l)          8.60±2.59      0.103   0.012       0.244
  Serum Cr (*μ*mol/l)   88.28±52.59    0.002   −8.3E-005   0.874
  TCH (mmol/l)          5.19±1.46      0.003   0.004       0.840
  TG (mmol/l)           2.21±1.48      0.049   0.015       0.427
  VLDL (mmol/l)         0.98±0.63      0.066   0.040       0.355
  HbA1c (%)             7.79±0.99      0.082   0.028       0.302
  HOMA-IR               1.50±0.69      0.004   −0.009      0.820

CatS, cathepsin S; Group DM, patients with type 2 diabetes; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; FPG, fasting plasma glucose; Cr, creatinine; TCH, cholesterol; TG, triglyceride; VLDL, very low density lipoprotein; HbAlc, glycosylated hemoglobin; HOMA-IR, homeostatic model assesment index of insulin resistance.

###### 

Relationship between serum CatS levels and clinical data in Group DM with a HbA1c level ≥9%.

  Clinical index        Mean ± SD      CatS             
  --------------------- -------------- ------- -------- -------
  Age (year)            54.69±10.03    0.018   0.001    0.429
  Course (year)         5.25±5.38      0.139   −0.006   0.025
  SBP (mmHg)            134.06±22.85   0.007   0.000    0.638
  DBP (mmHg)            77.03±8.06     0.034   −0.002   0.281
  BMI (kg/m^2^)         23.30±3.37     0.036   0.005    0.265
  FPG (mmol/l)          12.75±3.69     0.042   −0.005   0.231
  Serum Cr (*μ*mol/l)   76.21±39.18    0.106   0.001    0.053
  TCH (mmol/l)          4.87±1.15      0.018   0.010    0.435
  TG (mmol/l)           2.16±1.44      0.146   0.023    0.021
  VLDL (mmol/l)         0.99±0.64      0.144   0.052    0.022
  HbA1c (%)             14.60±4.27     0.026   0.003    0.346
  HOMA-IR               1.68±0.82      0.000   −0.002   0.900

CatS, cathepsin S; Group DM, patients with type 2 diabetes; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; FPG, fasting plasma glucose; Cr, creatinine; TCH, cholesterol; TG, triglyceride; VLDL, very low density lipoprotein; HbAlc, glycosylated hemoglobin; HOMA-IR, homeostatic model assesment index of insulin resistance.

###### 

Correlation between serum CatS levels and clinical data in Group DM with a BMI \<25 kg/m^2^.

  Index                 Mean ± SD      CatS             
  --------------------- -------------- ------- -------- -------
  Age (year)            56.06±10.04    0.017   0.001    0.448
  Course (year)         6.40±5.83      0.126   −0.005   0.033
  SBP (mmHg)            129.75±23.22   0.008   0.000    0.613
  DBP (mmHg)            76.11±8.31     0.044   −0.002   0.219
  BMI (kg/m^2^)         21.68±1.99     0.104   0.013    0.055
  FPG (mmol/l)          11.78±4.04     0.062   −0.005   0.143
  Serum Cr (*μ*mol/l)   79.19±47.31    0.016   0.000    0.466
  TCH (mmol/l)          4.87±1.38      0.064   0.014    0.137
  TG (mmol/l)           2.06±1.62      0.136   0.018    0.027
  VLDL (mmol/l)         0.93±0.71      0.142   0.042    0.023
  HbA1c (%)             11.94±3.99     0.040   −0.004   0.243
  HOMA-IR               1.54±0.79      0.000   0.000    0.981

CatS, cathepsin S; Group DM, patients with type 2 diabetes; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; FPG, fasting plasma glucose; Cr, creatinine; TCH, cholesterol; TG, triglyceride; VLDL, very low density lipoprotein; HbAlc, glycosylated hemoglobin; HOMA-IR, homeostatic model assesment index of insulin resistance.

###### 

Correlation between serum CatS levels and clinical data in Group DM with a BMI ≥25 kg/m^2^.

  Clinical index        Mean ± SD      CatS             
  --------------------- -------------- ------- -------- -------
  Age (year)            55.33±13.13    0.038   0.002    0.485
  Course (year)         3.63±3.01      0.008   −0.003   0.754
  SBP (mmHg)            146.80±17.61   0.007   0.001    0.767
  DBP (mmHg)            81.60±6.92     0.016   0.002    0.654
  BMI (kg/m^2^)         27.12±1.56     0.007   0.006    0.766
  FPG (mmol/l)          10.92±3.53     0.004   0.002    0.816
  Serum Cr (*μ*mol/l)   81.12±33.34    0.177   0.001    0.119
  TCH (mmol/l)          5.18±0.82      0.051   −0.033   0.418
  TG (mmol/l)           2.47±0.83      0.146   0.023    0.021
  VLDL (mmol/l)         1.11±0.37      0.118   0.110    0.210
  HbA1c (%)             14.16±6.16     0.053   0.004    0.409
  HOMA-IR               1.83±0.74      0.024   −0.025   0.580

CatS, cathepsin S; Group DM, patients with type 2 diabetes; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; FPG, fasting plasma glucose; Cr, creatinine; TCH, cholesterol; TG, triglyceride; VLDL, very low density lipoprotein; HbAlc, glycosylated hemoglobin; HOMA-IR, homeostatic model assesment index of insulin resistance.
